Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | STE/STE20/YSK protein kinase | 0.0205 | 0.2921 | 0.2636 |
Trypanosoma brucei | STE20-like serine/threonine-protein kinase 1, putative | 0.0105 | 0 | 0.5 |
Echinococcus multilocularis | serine:threonine protein kinase 3 | 0.0446 | 1 | 1 |
Trichomonas vaginalis | STE family protein kinase | 0.0205 | 0.2921 | 1 |
Schistosoma mansoni | ste20-related kinase | 0.0344 | 0.6997 | 1 |
Giardia lamblia | Kinase, STE STE20 | 0.0105 | 0 | 0.5 |
Echinococcus multilocularis | leucine rich repeat serine:threonine protein | 0.0118 | 0.0387 | 0.0387 |
Plasmodium falciparum | protein kinase, putative | 0.0205 | 0.2921 | 0.5 |
Plasmodium vivax | serine/threonine-specific protein kinase, putative | 0.0205 | 0.2921 | 0.5 |
Echinococcus multilocularis | serine threonine protein kinase | 0.0205 | 0.2921 | 0.2921 |
Brugia malayi | Protein kinase domain containing protein | 0.0166 | 0.1776 | 0.1445 |
Loa Loa (eye worm) | CAMK/CAMKL/CHK1 protein kinase | 0.0166 | 0.1776 | 0.1445 |
Echinococcus granulosus | serine threonine protein kinase | 0.0205 | 0.2921 | 0.2618 |
Leishmania major | protein kinase, putative | 0.0105 | 0 | 0.5 |
Trypanosoma cruzi | STE/STE20 serine/threonine-protein kinase, putative | 0.0105 | 0 | 0.5 |
Entamoeba histolytica | protein kinase, putative | 0.0205 | 0.2921 | 1 |
Trichomonas vaginalis | STE family protein kinase | 0.0205 | 0.2921 | 1 |
Loa Loa (eye worm) | STE/STE20/MST protein kinase | 0.0446 | 1 | 1 |
Trypanosoma cruzi | STE/STE20 serine/threonine-protein kinase, putative | 0.0105 | 0 | 0.5 |
Echinococcus granulosus | serine:threonine protein kinase 3 | 0.0446 | 1 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0205 | 0.2921 | 0.2193 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.